Companies › BioXcel Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Psychiatry; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Dexmedetomidine (BXCL501) Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 1 | Schizophrenia | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05025605 | Dexmedetomidine (BXCL501) | Phase 1 | Schizophrenia | Psychiatry | Jul 2027 |
Cash of $13m on 2026-06-30; operating cash outflow about $36m a year; runway about 4 months at that burn, to Nov 2026
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.